Live Breaking News & Updates on Development Therapeutic Areas

Stay updated with breaking news from Development therapeutic areas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer

Pfizer and Astellas announce positive top-line results from Phase 3 EMBARK trial
MARKHAM, ON, March 23, 2023 /CNW/ - Astellas Pharma Inc. , the parent company of Astellas Pharma Canada, Inc., has. | March 23, 2023 ....

United States , Chris Boshoff , Kenji Yasukawa , Ahsan Arozullah , Astellas Pharma Inc , American Society Of Clinical Oncology , Medivation Inc , Astellas Inc , European Union , Pfizer Global Product Development , Health Canada , Head Of Development Therapeutic Areas , Astellas Pharma Canada Inc , Pharma Inc , Pharma Canada , Senior Vice President , Development Therapeutic Areas , Chief Development Officer , Rare Disease , Pfizer Global Product , Non Metastatic Hormone Sensitive Prostate Cancer , High Risk Biochemical Recurrence , Focus Area Approach , Prostate Cancer , Clin Pract , Canada Newswire ,

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present detailed results from the Phase 3 GLOW. ....

New York , United States , United Kingdom , Kenji Yasukawa , Ahsan Arozullah , Rui Hua Xu , Manisha Shah , National Cancer Institute , American Society Of Clinical Oncology , Sun Yat Sen University Cancer Center , Department Of Medical Oncology , End Results Program , Astellas Pharma Inc , Head Of Development Therapeutic Areas , Gastrointestinal Oncology Program , Prnewswire Astellas Pharma Inc , American Cancer Society , Medical Oncology , March American Society , Clinical Oncology , Plenary Series , Medical Oncologist , Weill Cornell Medicine , Senior Vice President , Development Therapeutic Areas , Locally Advanced Unresectable Metastatic Gastric ,

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New York , United States , United Kingdom , Kenji Yasukawa , Ahsan Arozullah , Rui Hua Xu , Manisha Shah , National Cancer Institute , American Society Of Clinical Oncology , Sun Yat Sen University Cancer Center , Department Of Medical Oncology , Astellas Pharma Inc , End Results Program , Astellasastellas Pharma Inc , Head Of Development Therapeutic Areas , Gastrointestinal Oncology Program , Prnewswire Astellas Pharma Inc , American Cancer Society , Medical Oncology , March American Society , Clinical Oncology , Plenary Series , Medical Oncologist , Weill Cornell Medicine , Senior Vice President , Development Therapeutic Areas ,

XTANDI Plus Leuprolide Enhances MFS in Non-Metastatic Prostate Cancer

XTANDI Plus Leuprolide Enhances MFS in Non-Metastatic Prostate Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Kenji Yasukawa , Chris Boshoff , Ahsan Arozullah , Astellas Pharma Inc , Pfizer Inc , Head Of Development Therapeutic Areas , Drug Administration , Pfizer Global Product Development , Astellas Pharma , Chief Development Officer , Rare Disease , Pfizer Global Product , Senior Vice President , Development Therapeutic Areas ,

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

/PRNewswire/ Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive. ....

United States , Kenji Yasukawa , Chris Boshoff , Ahsan Arozullah , American Society Of Clinical Oncology , Prnewswire Pfizer Inc , Drug Administration , Pfizer Global Product Development , Lab Abnormalities , Astellas Inc , Exchange Commission , Astellas Pharma Inc , Pfizer Inc , European Union , Head Of Development Therapeutic Areas , Medivation Inc , Astellas Pharma , Chief Development Officer , Rare Disease , Pfizer Global Product , Senior Vice President , Development Therapeutic Areas , South America , Non Metastatic Hormone Sensitive Prostate Cancer , High Risk Biochemical Recurrence , Important Safety Information ,